La Jolla Pharmaceutical Company / Fundamentals
Income statement
- Net revenue
€39.66M - Cost of goods sold
€7.56M - Gross profit
€32.10M - SG&A expenses
€32.13M - R&D expenses
€2.15M - EBITDA
€13.45M - D&A
€1.53M - EBIT
-€2.19M - Interest expenses
€8.49M - EBT
€3.43M - Tax expenses
€2.13M - Net income
€1.30M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€795.80K - Changes in working capital
€1.27M - Operating cash flow
€11.20M - Capex
€7.68K - Other investing cash flow
-€122.82K - Net investing cash flow
€215.80K - Total cash dividends paid
€0.00 - Issuance of common stock
€507.51K - Debt repayment
€0.00 - Other financing cash flow
-€9.34M - Net financing cash flow
-€9.34M - Foreign exchange effects
€7.68K - Net change in cash
€2.09M - Cash at end of period
€41.26M - Free cash flow
€11.21M
Balance sheet
- Cash and cash equivalents
€41.23M - Cash and short-term investments
€41.51M - Total receivables
€5.06M - Inventory
€7.08M - Other current assets
€2.96M - Total current assets
€56.60M - Property, plant & equipment
€253.33K - Goodwill
€17.16M - Intangible assets
€10.70M - Long-term investments
€0.00 - Other non-current assets
€34.12K - Total non-current assets
€28.15M - Total assets
€84.75M - Accounts payable
€1.81M - Short-term debt
€133.91K - Other current liabilities
€9.69M - Total current liabilities
€14.07M - Long-term debt
€63.97K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€129.88M - Total non-current liabilities
€129.94M - Total liabilities
€144.01M - Common stock
€2.56K - Retained earnings
-€899.55M - Other equity
€0.00 - Total equity
-€59.25M - Total liabilities and shareholders' equity
€84.75M
Company information
- Market capitalization
€0.00 - Employees
61 - Enterprise Value
-€44.03M
Company ratios
- Gross margin
-
80.9% Much better than peer group: -1,039,606,129,814.8% - EBITDA margin
-
33.9% Much better than peer group: -2,459,188,856,135.2% - EBIT margin
-
-5.5% Much better than peer group: -2,600,490,118,837.1% - EBT margin
-
8.6% Much better than peer group: -2,495,469,937,291.5% - Net margin
-
3.3% Much better than peer group: -2,495,469,934,536.2% - ROE
-
-2.2% Much better than peer group: -144.9% - ROA
-
1.5% Much better than peer group: -2,607.3% - Asset turnover
-
46.8% Much worse than peer group: 93.3% - FCF margin
-
28.2% Much better than peer group: -2,078,984,395,766.1% - FCF yield
0.0% - Efficiency ratio
66.1% - Net sales per employee
-
€650.09K - Net income per employee
-
€21.27K